T1	Participants 102 221	patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both
T2	Participants 577 706	patients with systolic dysfunction and heart failure receiving therapeutic inhibition of the renin-angiotensin-aldosterone system
T3	Participants 888 927	768 treated patients with heart failure
